Sarepta Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris from BMO Capital upgraded the rating on the stock to a Buy and gave it a $50.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Buy rating due to a combination of factors that suggest Sarepta Therapeutics is well-positioned for future growth. Despite concerns about potential risks associated with Elevidys, particularly regarding patient safety, the current valuation of Sarepta’s stock appears favorable. The analyst notes that the uptake of Elevidys is increasing, with sales projections for late 2025 potentially exceeding expectations.
Furthermore, upcoming readouts from Sarepta’s DM1 and FSHD programs could diversify the company’s portfolio and attract new investors. These programs, although in early stages, have the potential to establish Sarepta as a significant player in lucrative markets. While the risk of adverse events remains, the likelihood of significant market impact is mitigated by the continued prescription of Elevidys and the high unmet medical need it addresses.
In another report released on September 15, Guggenheim also reiterated a Buy rating on the stock with a $22.00 price target.